HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVATES THE CLASSICAL PATHWAY OF COMPLEMENT BY DIRECT C1-BINDING THROUGH SPECIFIC SITES IN THE TRANSMEMBRANE GLYCOPROTEIN-GP41

被引:192
作者
EBENBICHLER, CF
THIELENS, NM
VORNHAGEN, R
MARSCHANG, P
ARLAUD, GJ
DIERICH, MP
机构
[1] INST HYG,A-6010 INNSBRUCK,AUSTRIA
[2] CTR ETUD NUCL GRENOBLE,DBMS,BEP,F-38041 GRENOBLE,FRANCE
[3] BIOTEST,W-6072 DREIEICH,GERMANY
关键词
D O I
10.1084/jem.174.6.1417
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus type 1 (HIV-1), in contrast to animal retroviruses such as murine leukemia virus, is not lysed by human complement. Nevertheless, HIV-1 activates complement via the classical pathway independent of antibody, and C3b deposition facilitates infection of complement receptor-bearing cells. Using gel exclusion chromatography on Sephacryl S-1000, purified virions were found to bind I-125-labeled C1q, but not I-125-labeled dimeric proenzyme C1s. Virions activated the C1 complex, reconstituted from C1q, proenzyme C1r, and I-125-labeled proenzyme C1s, to an extent comparable with that obtained with immunoglobulin G-ovalbumin immune complexes. To determine the activating viral component, recombinant viral proteins were used: in the solid phase, soluble gp41 (sgp41) (the outer membrane part of gp41, residues 539-684 of gp160) bound C1q, but not dimeric proenzyme C1s, while gp120 was ineffective. In the fluid phase, sgp41 activated the C1 complex in a dose- and time-dependent manner, more efficiently than aggregated Ig, but less efficiently than immune complexes. To localize the C1 activating site(s) in gp41, synthetic peptides (15-residue oligomers spanning amino acids 531-695 of gp160) were used. Peptides covering positions 591-605 and 601-620 and, to a lesser extent, positions 561-575, had both the ability to bind C1q and to induce C3 deposition. These data provide the first experimental evidence of a direct interaction between the C1 complex and HIV-1, and indicate that C1 binding and activation are mediated by specific sites in gp41.
引用
收藏
页码:1417 / 1424
页数:8
相关论文
共 63 条
[1]   PURIFIED PROENZYME C1R - SOME CHARACTERISTICS OF ITS ACTIVATION AND SUBSEQUENT PROTEOLYTIC CLEAVAGE [J].
ARLAUD, GJ ;
VILLIERS, CL ;
CHESNE, S ;
COLOMB, MG .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 616 (01) :116-129
[2]   DIFFERENTIAL ELUTION OF CLQ, CLR AND CLS FROM HUMAN CL BOUND TO IMMUNE AGGREGATES - USE IN THE RAPID PURIFICATION OF CL SUB-COMPONENTS [J].
ARLAUD, GJ ;
SIM, RB ;
DUPLAA, AM ;
COLOMB, MG .
MOLECULAR IMMUNOLOGY, 1979, 16 (07) :445-450
[3]   SEPARATION OF SELF FROM NON-SELF IN THE COMPLEMENT-SYSTEM [J].
ATKINSON, JP ;
FARRIES, T .
IMMUNOLOGY TODAY, 1987, 8 (7-8) :212-215
[4]   THE AIDS-ASSOCIATED RETROVIRUS IS NOT SENSITIVE TO LYSIS OR INACTIVATION BY HUMAN-SERUM [J].
BANAPOUR, B ;
SERNATINGER, J ;
LEVY, JA .
VIROLOGY, 1986, 152 (01) :268-271
[5]   MECHANISM OF ANTIBODY-INDEPENDENT ACTIVATION OF THE 1ST COMPONENT OF COMPLEMENT (CL) ON RETROVIRUS MEMBRANES [J].
BARTHOLOMEW, RM ;
ESSER, AF .
BIOCHEMISTRY, 1980, 19 (13) :2847-2853
[6]   LYSIS OF ONCORNAVIRUSES BY HUMAN-SERUM - ISOLATION OF VIRAL COMPLEMENT (C1) RECEPTOR AND IDENTIFICATION AS P15E [J].
BARTHOLOMEW, RM ;
ESSER, AF ;
EBERHARD, HJM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 147 (03) :844-853
[7]   COMPLEMENT MEDIATES HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF A HUMAN T-CELL LINE IN A CD4-INDEPENDENT AND ANTIBODY-INDEPENDENT FASHION [J].
BOYER, V ;
DESGRANGES, C ;
TRABAUD, MA ;
FISCHER, E ;
KAZATCHKINE, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (05) :1151-1158
[8]   IDENTIFICATION OF AN ADDITIONAL CLASS OF C3-BINDING MEMBRANE-PROTEINS OF HUMAN PERIPHERAL-BLOOD LEUKOCYTES AND CELL-LINES [J].
COLE, JL ;
HOUSLEY, GA ;
DYKMAN, TR ;
MACDERMOTT, RP ;
ATKINSON, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (03) :859-863
[9]   LYSIS OF RNA TUMOR-VIRUSES BY HUMAN-SERUM - DIRECT ANTIBODY-INDEPENDENT TRIGGERING OF CLASSICAL COMPLEMENT PATHWAY [J].
COOPER, NR ;
JENSEN, FC ;
WELSH, RM ;
OLDSTONE, MBA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 144 (04) :970-984
[10]  
COOPER NR, 1978, J IMMUNOL, V120, P1862